Johnson & Johnson will supply up to 400 million doses of its COVID-19 vaccine to the E.U. and 300 million doses to the U.S. contingent on clinical trial success and regulatory approvals. By the end of next year, the company expects to have the capacity to manufacture 1 billion doses of the vaccine per year. At $10 per dose, that spells a potential $10 billion in annual revenue from a vaccine, on top of the $80.68 billion Johnson & Johnson already brings in from internationally commercialized products.